Muscle mass as a resilence factor for endothelial health in obesity
February 2, 2026 / obesity / muscle mass / endothelial health / cardiovascular risk / body composition
Skeletal muscle mass may serve as a protective resilience factor against endothelial dysfunction in obesity, shifting focus from body mass alone to body composition in assessing cardiovascular risk and evaluating obesity treatments.
A new approach to weight loss and metabolic health puts personalized care and long-term results first
January 28, 2025 / weight loss / metabolic health / personalized care / obesity treatment / diabetes management
AdventHealth’s Metabolic Health Institute offers a personalized, multidisciplinary approach to weight loss and metabolic care, integrating medical, surgical, and lifestyle interventions to support sustainable outcomes for obesity, diabetes, and related conditions.
AstraZeneca Beefs Up in Metabolic Disease, Paying $1.2B to Partner on CSPC Obesity & Diabetes Meds
January 30, 2026 / AstraZeneca / obesity treatment / diabetes drugs / GLP-1 GIP agonist / metabolic disease
AstraZeneca is investing $1.2B to co-develop CSPC’s AI-driven, once-monthly obesity and diabetes drugs, expanding its metabolic disease pipeline with next-generation GLP-1/GIP agonists aimed at improving adherence and long-term treatment outcomes.
Sleeve gastrectomy may produce greater and more durable weight loss than semaglutide in patients with obesity
January 30, 2026 / sleeve gastrectomy / semaglutide / obesity treatment / weight loss durability / metabolic outcomes
Sleeve gastrectomy led to significantly greater and more sustained weight loss than semaglutide over 12 months, with better metabolic improvements; semaglutide’s benefits diminished after discontinuation, emphasizing the need for long-term pharmacologic strategies in obesity treatment.
The ‘yo-yo effect’ impairs metabolism and reduces brown fat activity in women
February 2, 2026 / yo-yo dieting / brown fat / metabolic health / obesity treatment / women’s health
Yo-yo dieting in women is linked to increased body fat, impaired metabolism, and reduced brown fat activity, highlighting the need for obesity care focused on sustainable fat loss, muscle preservation, and long-term metabolic health improvements.
Vitamin D Shows Potential in Managing Metabolic Health for Diabetes
January 31, 2026 / vitamin D / glycemic control / type 2 diabetes / insulin sensitivity / pharmacist education
High-dose vitamin D3 modestly improves glycemic control in obese type 2 diabetes patients by enhancing insulin sensitivity, though it doesn’t impact BMI or blood pressure, underscoring the need for pharmacist education on supplement use in metabolic care.
GLP-1 drugs don’t work for everyone. But personalized obesity care in the future might
January 27, 2026 / GLP-1 drugs / personalized obesity care / precision medicine / genetic testing / hormone imbalance
GLP-1 drugs show promise but aren’t effective for all, underscoring obesity’s complex, individualized roots. Future care will focus on precision medicine—using genetic, hormonal, and behavioral data to personalize obesity treatment for sustainable, long-term outcomes.
Eating melatonin-rich foods is linked to lower obesity and depression rates
January 28, 2026 / melatonin foods / obesity prevention / depression risk / metabolic health / dietary patterns
Higher intake of melatonin-rich foods was associated with lower rates of obesity and depression in adults, suggesting dietary melatonin may support metabolic and mental health by aligning with endogenous circadian rhythms and reducing inflammation.
Berberine shows no advantage over placebo for reducing liver and belly fat
January 28, 2026 / berberine / liver fat / visceral adiposity / MASLD treatment / obesity management
In adults with obesity and MASLD, six months of oral berberine showed no significant reduction in visceral or liver fat versus placebo, though modest improvements in lipid and inflammation markers were observed, highlighting limited efficacy for fat reduction.
Night owl or early bird: Chronotype can influence your health and muscle strength
January 30, 2026 / chronotype / muscle health / metabolic function / sarcopenic obesity / personalized care
Chronotype influences muscle strength, metabolism, and overall health, with evening types at greater risk for sarcopenic obesity and metabolic dysfunction. Personalized health strategies considering sleep, meal timing, and activity patterns may enhance outcomes in obesity and aging-related care.
New Drug Stops Weight Gain and Lowers Cholesterol by Targeting Nitric Oxide
January 29, 2026 / nitric oxide / obesity treatment / cholesterol reduction / fat metabolism / SCoR2 enzyme
Blocking the newly identified enzyme SCoR2, which removes nitric oxide from fat-regulating proteins, prevented weight gain and reduced cholesterol in mice—suggesting a novel therapeutic target for obesity, metabolic dysfunction, and fatty liver disease.
insitro Completes First AI-Enabled Human Genetics Study of Brown Adipose Tissue, Shares Differentiated Targets with Anti-Obesity Effects
February 2, 2026 / brown fat / AI genetics / obesity therapy / BAT-01 target / metabolic health
insitro used AI-driven genetics to identify and validate brown adipose tissue (BAT) targets, including BAT-01, which reduced fat and preserved lean mass in obese mice—offering a novel, appetite-independent pathway for future obesity and cardiometabolic therapies.
Korea’s Hanmi Pharma secures export deal with Mexican partner Sanfer for GLP-1 obesity drug and more
January 28, 2026 / GLP-1 therapy / obesity treatment / diabetes drug / efpeglenatide / Hanmi Sanfer deal
Hanmi Pharma signed an exclusive deal with Mexico’s Sanfer to distribute its GLP-1 obesity drug efpeglenatide and Dapalon diabetes therapies, advancing regulatory filings and expanding indications to address Mexico’s high obesity and diabetes burden.
MASH Drug Efficacy Varied Widely Across Fibrosis, Resolution Outcomes
January 30, 2026 / MASH treatment / liver fibrosis / pegozafermin / metabolic liver disease / drug efficacy
Clinical trial data show wide variability in MASH drug efficacy, with pegozafermin leading for fibrosis regression and resolution, underscoring the need for head‑to‑head and long‑term studies to guide treatment selection beyond histologic endpoints.
Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development
February 2, 2025 / pemvidutide / GLP-1 agonist / MASH treatment / Altimmune pipeline / liver disease
Altimmune’s lead candidate, pemvidutide—a GLP-1/glucagon dual agonist—advances toward Phase 3 for MASH after promising Phase 2b results and Breakthrough Therapy Designation, positioning the company as a rising player in metabolic and liver disease therapeutics.
Aiming for MASH Resolution: How to Use GLP‑1s in Liver‑First Diabetes Care
January 30, 2026 / MASH treatment / GLP-1 therapy / liver-first care / metabolic disease / type 2 diabetes
GLP-1 and dual GIP/GLP-1 therapies offer promising benefits for patients with type 2 diabetes and MASH by reducing liver fat, improving metabolic health, and addressing fibrosis risk—supporting a liver-first, personalized treatment approach with ongoing monitoring.
Study reveals hidden bacterial role in the formation of most kidney stones
January 27, 2026 / kidney stones / calcium oxalate / bacterial biofilms / urinary tract infections / stone formation
UCLA researchers discovered live bacteria and biofilms within calcium oxalate kidney stones, revealing a hidden microbial role in stone formation and potential links to recurrent UTIs—offering a novel therapeutic target for prevention and treatment.
Scientists Reveal Two-Day Diet That Slashes Cholesterol for Weeks
January 27, 2026 / oatmeal diet / LDL cholesterol / metabolic syndrome / heart health / dietary intervention
A two-day oatmeal-based diet significantly reduced LDL cholesterol by ~10% in individuals with metabolic syndrome, with effects lasting up to six weeks—highlighting a simple, short-term dietary intervention for improving cardiometabolic risk.
Elevated BMI, physical inactivity are metabolic drivers of hypertension-related chronic kidney disease
January 30, 2025 / chronic kidney disease / elevated BMI / physical inactivity / hypertension risk / metabolic drivers
Elevated BMI and physical inactivity are key modifiable drivers of hypertension-related chronic kidney disease, with BMI having a greater global impact on mortality and disability—highlighting the urgent need for targeted interventions to reduce HT-CKD burden.